Back to Search Results
Image Place holder

Eric Padron, MD

 
Specialty: Medical Oncology
Sub Specialty: Medical Oncology, Hematology
Program: Malignant Hematology

Google Scholar Profile


Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Leukemia, MDS, Myelodysplastic Syndromes (MDS)

Dr. Eric Padron is an assistant member in the Malignant Hematology program in the Department of Malignant Hematology, and the Chemical Biology and Molecular Medicine Program.  Dr. Padron’s clinical interests are the care and treatment of patients with adult myeloid malignancies including MDS, AML and Myeloproliferative Neoplasms (MPs) with a specific interest in the Myeloproliferative/Myelodysplastic (MDS/MPN) syndromes of which CMML is a member.    


Education & Training

Board Certification:

  • Internal Medicine - Medical Oncology
  • Internal Medicine - Hematology

Fellowship:

  • Moffitt Cancer Center - Hematology/Oncology

Residency:

  • University of Florida Shands Hospital -

Medical School:

  • University of South Florida - MD
Awards
Start Year: 2011 End Year: 2011 Scientific Symposium Outstanding Poster Award, Sponsor: Moffitt Cancer Center & Research Institute
Start Year: 2014 End Year: Miles for Moffitt Award, Sponsor: Moffitt Cancer Center
Start Year: 2016 End Year: Junior Faculty Award, Sponsor: Moffitt Cancer Center
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Jun.7(8):e601-e612. Pubmedid: 32563283. Pmcid: PMC7302757.
  • Badaat I, Mirza S, Padron E, Sallman D, Komrokji R, Song J, Hussaini MO. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. J Clin Pathol. 2020 Apr.73(4):209-212. Pubmedid: 31771970.
  • Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: 31357093. Pmcid: PMC7375354.
  • Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019 Oct.33(10):2466-2480. Pubmedid: 30894665.
  • Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 Oct.104(10):1935-1949. Pubmedid: 31048353. Pmcid: PMC6886439.
  • McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019 Nov.3(22):3579-3589. Pubmedid: 31738830. Pmcid: PMC6880887.
  • Rose A, Slone S, Padron E. Relapsed Acute Lymphoblastic Leukemia Presenting as Acute Renal Failure. Case Rep Nephrol. 2019 May.2019:7913027. Pubmedid: 31214367. Pmcid: PMC6535833.
  • Badar T, Johnson L, Trifilo K, Wang H, Kudlow BA, Padron E, Pappenhausen PR, Hussaini MO. Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing. Appl Immunohistochem Mol Morphol. 2019 Mar.27(3):e28-e31. Pubmedid: 28187034.
  • Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar.19(3):157-161. Pubmedid: 30713125.
  • Chung J, Sallman DA, Padron E. TP53 and therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2019 Mar.32(1):98-103. Pubmedid: 30927980.
  • Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan.37(1):7-11. Pubmedid: 30403571. Pmcid: PMC6354773.
  • Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Sci Rep. 2019 Jan.9(1):606. Pubmedid: 30679640. Pmcid: PMC6345777.
  • Letson C, Padron E. Non-canonical transcriptional consequences of BET inhibition in cancer. Pharmacol Res. 2019 Dec.150:104508. Pubmedid: 31698067.
  • Kuykendall AT, Padron E. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. Curr Hematol Malig Rep. 2019 Dec.14(6):543-549. Pubmedid: 31776774.
  • Vedder AR, Miedel EL, Ragland NH, Balasis ME, Letson CT, Engelman RW, Padron E. Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice. Comp Med. 2019 Aug.69(4):276-282. Pubmedid: 31349880. Pmcid: PMC6733163.
  • Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr.19(4):251-254. Pubmedid: 30852241.
  • Ferrall-Fairbanks MC, Ball M, Padron E, Altrock PM. Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. JCO Clin Cancer Inform. 2019 Apr.3:1-10. Pubmedid: 30995123. Pmcid: PMC6873939.
  • Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018 Sep.5(9):e393-e402. Pubmedid: 30072146. Pmcid: PMC6505461.
  • Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW. OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A. 2018 Oct.93(10):982-986. Pubmedid: 30347519. Pmcid: PMC6484443.
  • Hunter AM, Zhang L, Padron E. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. CURR TREAT OPTION ON. 2018 Oct.19(12):67. Pubmedid: 30367269.
  • Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018 Nov.2(6):e150. Pubmedid: 31723789. Pmcid: PMC6745959.
  • Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018 May.24(4):497-504. Pubmedid: 29457796. Pmcid: PMC6730556.
  • Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018 May.31:174-181. Pubmedid: 29728305. Pmcid: PMC6013781.
  • Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: 29189896.
  • Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: 29496691. Pmcid: PMC5892606.
  • Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018 Feb.97(2):247-254. Pubmedid: 29167940.
  • Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, Montgomery ND, Bolton K, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp S, Levine R, Papaemmanuil E, Zehir A, Hayes DN, Padron E. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clin Cancer Res. 2018 Dec.24(23):5918-5924. Pubmedid: 29866652. Pmcid: PMC6812550.
  • Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Dec.16(12):1500-1537. Pubmedid: 30545997.
  • Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Ne. 2017 Oct.15(10):1193-1207. Pubmedid: 28982745.
  • Gillis NK, Padron E. Chipping in on clonal hematopoiesis. Oncotarget. 2017 Oct.8(49):84637-84638. Pubmedid: 29156670. Pmcid: PMC5689560.
  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: 28006850.
  • Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Jun.31(6):1391-1397. Pubmedid: 28111463.
  • Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan.17(1):7-13. Pubmedid: 27771290.
  • Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb.22(2):144-151. Pubmedid: 28179575. Pmcid: PMC5330702.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: 28869184.
  • Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: 29030092.
  • Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Apr.17(4):211-214. Pubmedid: 28185797.
  • Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017 11.7(12):633. Pubmedid: 29176559. Pmcid: PMC5802523.
  • Sallman DA, Padron E. Myelodysplasia in younger adults: outlier or unique molecular entity?. Haematologica. 2017 06.102(6):967-968. Pubmedid: 28566339. Pmcid: PMC5451326.
  • Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 03.31(3):767-768. Pubmedid: 27740632.
  • Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016 Sep.9(3):89-95. Pubmedid: 27187622.
  • Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016 Sep.13(3):360-372. Pubmedid: 27807503. Pmcid: PMC5069836.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May.91(5):E280-E283. Pubmedid: 26875020.
  • Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar.42:52-58. Pubmedid: 26894965.
  • Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar.30(3):666-673. Pubmedid: 26514544. Pmcid: PMC7864381.
  • Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016 Feb.7:10767. Pubmedid: 26908133. Pmcid: PMC4770084.
  • Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Curr Hematol Malig Rep. 2016 Dec.11(6):425-433. Pubmedid: 27664113.
  • Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S64-S66. Pubmedid: 27521328.
  • Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S53-S56. Pubmedid: 27521325.
  • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 08.101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
  • Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015 Sep.100(9):1117-1130. Pubmedid: 26341525. Pmcid: PMC4800699.
  • Bell GC, Padron E. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling. Leuk Res Rep. 2015 Sep.4(2):70-71. Pubmedid: 26716078. Pmcid: PMC4672079.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. Am J Hematol. 2015 Nov.90(11):1036-1040. Pubmedid: 26284571.
  • Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov.15(11):705-710. Pubmedid: 26440749.
  • Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar.121(6):876-882. Pubmedid: 25410759. Pmcid: PMC4378905.
  • Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015 Mar.22(2):163-170. Pubmedid: 25575034.
  • Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol. 2015 Mar.22(2):146-154. Pubmedid: 25575032.
  • Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar.125(12):1857-1865. Pubmedid: 25624319. Pmcid: PMC4915792.
  • Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S60-S63. Pubmedid: 26297280.
  • Sallman DA, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S50-S55. Pubmedid: 26297278.
  • Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S14-S18. Pubmedid: 26297266.
  • Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul.39(7):673-678. Pubmedid: 25934048. Pmcid: PMC5992898.
  • Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul.5:e333. Pubmedid: 26230957. Pmcid: PMC4526779.
  • Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015 Jan.39(1):6-17. Pubmedid: 25465125.
  • Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015 Jan.5:e270. Pubmedid: 25555161. Pmcid: PMC5404217.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. Am J Hematol. 2015 Aug. Pubmedid: 26260295. Pmcid: PMC4751065.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015 Apr.133(2):249-256. Pubmedid: 25413011.
  • Padron E. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. Hematology Am Soc Hematol Educ Program. 2015.2015:349-354. Pubmedid: 26637742.
  • Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar.12(3):172-178. Pubmedid: 24927265.
  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun.123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.
  • Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug.89(8):809-812. Pubmedid: 24764152. Pmcid: PMC4561860.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: 24439565.
  • Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep.13 Suppl 2:S295-S299. Pubmedid: 24290214.
  • Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct.6(5):485-487. Pubmedid: 24083503.
  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun.121(25):5068-5077. Pubmedid: 23632888. Pmcid: PMC4347259.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul.88(7):566-570. Pubmedid: 23605934. Pmcid: PMC4685468.
  • Padron E, Abdel-Wahab O. Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol. 2013 Jul.31(19):2374-2376. Pubmedid: 23690427.
  • Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul.27(7):1504-1510. Pubmedid: 23531518.
  • Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec.26(4):365-375. Pubmedid: 24507813.
  • Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct.19(4 Suppl):4-15. Pubmedid: 23042420.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov.87(11):1006-1009. Pubmedid: 23090887.
  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May.118(10):2659-2664. Pubmedid: 21956402.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar.2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb.3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.
  • Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011 Mar.(62):71.
  • Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb.4(1):61-69. Pubmedid: 21322779.
  • Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec.12(4):354-368. Pubmedid: 21964863.
  • Lane MD, Nam HJ, Padron E, Gurda-Whitaker B, Kohlbrenner E, Aslanidi G, Byrne B, McKenna R, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crytstallogr F. 2005 Jun.61(Pt 6):558-561. Pubmedid: 16511095. Pmcid: PMC1952340.
  • Kaludov N, Padron E, Govindasamy L, McKenna R, Chiorini JA, Agbandje-McKenna M. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4. Virology. 2003 Feb.306(1):1-6. Pubmedid: 12620791.

Grants

Title: The National Myelodysplastic Syndromes Natural History Study (The National MDS Study)
Sponsor: Nat Institutes of Health
PI (Contact): Rollison, D., PI (MPI): Padron, E.
Title: Cytokine-dependent Genetic Selection in Chronic Myelomonocytic Leukemia
Sponsor: Amer Cancer Society
PI: Padron, E.
Title: Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
Sponsor: Nat Institutes of Health
PI: Padron, E.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments